Peptide drugs are synthetic short chains of amino acids that mimic natural hormones to manage complex metabolic, endocrine, and oncological conditions. Peptide drugs target receptors with high specificity, therefor offer exceptional efficacy and minimal off-target toxicity compared to traditional small-molecule drugs. Examples of peptide drugs The peptide drug universe is expanding rapidly. Some of […]
Peptide drugs are synthetic short chains of amino acids that mimic natural hormones to manage complex metabolic, endocrine, and oncological conditions. Peptide drugs target receptors with high specificity, therefor
Metabolic-dysfunctional Associated SteatoHepatitis (MASH) is rising globally but effective treatment is limited. It is characterized by inflammation and variable fibrosis, which can progress to cirrhosis and hepatocellular carcinoma.
The remarkable clinical success of targeted therapies, immunotherapies, antibody-drug conjugates (ADCs), and targeted protein degraders (TPDs) has substantially improved outcomes for many cancer patients. Nevertheless, durable therapeutic responses remain
INTRODUCTION Targeted protein degradation (TPD) has emerged as a transformative therapeutic modality in modern drug discovery. Unlike conventional small-molecule inhibitors, which typically suppress protein function through occupancy-driven mechanisms,
Introduction Chimeric antigen receptor (CAR) T-cell therapy has demonstrated unprecedented clinical efficacy in the treatment of hematologic malignancies; however, primary resistance and disease relapse remain significant barriers to durable
T-cell dysfunction is a major obstacle to effective immunotherapy in cancer, chronic infection, and autoimmune disease, where persistent antigen exposure and immunosuppressive signaling lead to impaired proliferation, reduced effector
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for hematologic malignancies, yet its efficacy in solid tumors remains limited by poor persistence, T-cell exhaustion, and an immunosuppressive tumor
The emergence of immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines has underscored the importance of understanding tumor immunobiology at a systems level. Immuno-oncology research increasingly relies on
G Protein-Coupled Receptors (GPCRs) in the Immune System The human genome encodes approximately 800 G protein–coupled receptors (GPCRs), representing a structurally conserved yet functionally diverse superfamily that underpins
Fibrosis is a final common pathological end-point of chronic injury in multiple organs, characterized by persistent myofibroblast activation, excessive extracellular matrix (ECM) deposition, and progressive organ dysfunction. Although
